- In January 2025, advances in SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology have significantly enhanced the selection process of high-affinity aptamers, particularly RNA aptamers, improving their stability and specificity. These developments are expected to boost their application in diagnostics, targeted drug delivery, and biosensing platforms
- In November 2024, according to a market analysis by The Business Research Company, the global aptamers market is witnessing strong momentum, driven by increased adoption in therapeutic applications, including cancer treatment and rare disease diagnostics. The report highlights ongoing collaborations between biotech firms and academic institutions to accelerate aptamer-based drug discovery
- In October 2024, IMARC Group reported substantial investments in the North American aptamers market, with the U.S. leading due to a high volume of clinical research and trials involving aptamer-based therapeutics. Increased government and private sector funding have further accelerated product development in precision medicine
- In March 2022, Aptamer Sciences selected a promising candidate for its COVID-19 virus-neutralizing aptamer, aimed at supporting non-clinical research in the development of treatments and vaccines for the virus.
- In July 2021, Aptamer Sciences identified a potential COVID-19 neutralizing aptamer candidate, advancing it to support preclinical efforts in the treatment and vaccine development for the virus
